دورية أكاديمية
أعرض في EDS

Investigating the consistency of extracellular vesicle production from breast cancer subtypes using CELLine adherent bioreactors.

التفاصيل البيبلوغرافية
العنوان: Investigating the consistency of extracellular vesicle production from breast cancer subtypes using CELLine adherent bioreactors.
المؤلفون: Hisey CL; Hub for Extracellular Vesicle Investigations University of Auckland Auckland New Zealand.; Department of Obstetrics and Gynaecology University of Auckland Auckland New Zealand., Artuyants A; Hub for Extracellular Vesicle Investigations University of Auckland Auckland New Zealand.; Auckland Cancer Society Research Centre University of Auckland Auckland New Zealand., Guo G; Department of Physiology School of Medical Sciences University of Auckland Auckland New Zealand., Chang V; Hub for Extracellular Vesicle Investigations University of Auckland Auckland New Zealand.; Department of Obstetrics and Gynaecology University of Auckland Auckland New Zealand., Reshef G; Department of Molecular Medicine and Pathology University of Auckland Auckland New Zealand., Middleditch M; School of Biological Sciences University of Auckland Auckland New Zealand., Jacob B; School of Biological Sciences University of Auckland Auckland New Zealand., Chamley LW; Hub for Extracellular Vesicle Investigations University of Auckland Auckland New Zealand.; Department of Obstetrics and Gynaecology University of Auckland Auckland New Zealand., Blenkiron C; Hub for Extracellular Vesicle Investigations University of Auckland Auckland New Zealand.; Auckland Cancer Society Research Centre University of Auckland Auckland New Zealand.; Department of Molecular Medicine and Pathology University of Auckland Auckland New Zealand.
المصدر: Journal of extracellular biology [J Extracell Biol] 2022 Sep 22; Vol. 1 (9), pp. e60. Date of Electronic Publication: 2022 Sep 22 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles Country of Publication: United States NLM ID: 9918382980506676 Publication Model: eCollection Cited Medium: Internet ISSN: 2768-2811 (Electronic) Linking ISSN: 27682811 NLM ISO Abbreviation: J Extracell Biol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Hoboken, New Jersey] : Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles, [2022]-
مستخلص: Extracellular vesicle (EV) research has grown rapidly in recent years, largely due to the potential use of EVs as liquid biopsy biomarkers or therapeutics. However, in-depth characterisation and validation of EVs produced using conventional in vitro cultures can be challenging due to the large area of cell monolayers and volumes of culture media required. To overcome this obstacle, multiple bioreactor designs have been tested for EV production with varying success, but the consistency of EVs produced over time in these systems has not been reported previously. In this study, we demonstrate that several breast cancer cell lines of different subtypes can be cultured simultaneously in space, resource, and time efficient manner using CELLine AD 1000 systems, allowing the consistent production of vast amounts of EVs for downstream experimentation. We report an improved workflow used for inoculating, maintaining, and monitoring the bioreactors, their EV production, and the characterisation of the EVs produced. Lastly, our proteomic analyses of the EVs produced throughout the lifetime of the bioreactors show that core EV-associated proteins are relatively consistent, with few minor variations over time, but that tracking the production of EVs is a convenient method to indirectly monitor the bioreactor and consistency of the yielded EVs. These findings will aid future studies requiring the simultaneous production of large amounts of EVs from several cell lines of different subtypes of a disease and other EV biomanufacturing applications.
Competing Interests: The authors have no conflicts of interest to disclose.
(© 2022 The Authors. Journal of Extracellular Biology published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles.)
References: Bioact Mater. 2022 Aug 02;25:732-747. (PMID: 37056276)
Proteomes. 2017 Oct 08;5(4):. (PMID: 28991197)
J Cancer. 2017 Sep 12;8(16):3131-3141. (PMID: 29158785)
Proteomics. 2014 Mar;14(6):699-712. (PMID: 24376083)
Adv Sci (Weinh). 2018 Dec 20;6(4):1800948. (PMID: 30828519)
World J Clin Oncol. 2014 Aug 10;5(3):412-24. (PMID: 25114856)
JCI Insight. 2018 Apr 19;3(8):. (PMID: 29669940)
J Extracell Vesicles. 2019 Apr 04;8(1):1596669. (PMID: 31007875)
Front Cell Dev Biol. 2020 Mar 12;8:149. (PMID: 32226787)
PLoS Biol. 2019 Jul 18;17(7):e3000363. (PMID: 31318874)
J Extracell Vesicles. 2018 Feb 28;7(1):1442088. (PMID: 29535850)
Sex Med. 2019 Jun;7(2):241-250. (PMID: 30910509)
Exp Mol Med. 2019 Mar 15;51(3):1-12. (PMID: 30872574)
Cell Commun Signal. 2020 Sep 25;18(1):158. (PMID: 32988382)
Front Cell Dev Biol. 2020 Nov 03;8:553444. (PMID: 33224943)
Signal Transduct Target Ther. 2020 Aug 3;5(1):144. (PMID: 32747657)
Nat Protoc. 2009;4(1):44-57. (PMID: 19131956)
Stem Cell Res Ther. 2020 May 27;11(1):206. (PMID: 32460853)
Colloids Surf B Biointerfaces. 2021 Jul;203:111772. (PMID: 33894649)
J Immunol Methods. 2008 Jun 1;335(1-2):98-105. (PMID: 18423480)
Nanoscale. 2018 Jan 18;10(3):881-906. (PMID: 29265147)
PLoS One. 2019 Jan 4;14(1):e0210003. (PMID: 30608951)
Biomaterials. 2016 Oct;105:195-205. (PMID: 27522254)
Nat Commun. 2020 Aug 26;11(1):4261. (PMID: 32848136)
Cells. 2020 Sep 04;9(9):. (PMID: 32899718)
Biotechnol Adv. 2018 Dec;36(8):2051-2059. (PMID: 30218694)
Biochem Biophys Rep. 2021 May 25;26:101026. (PMID: 34095553)
Reproduction. 2022 Aug 25;164(4):143-154. (PMID: 35938796)
PLoS Biol. 2012;10(12):e1001450. (PMID: 23271954)
Nat Commun. 2021 Jul 19;12(1):4389. (PMID: 34282141)
Cell Mol Bioeng. 2019 Dec 23;13(1):1-16. (PMID: 32030104)
ACS Nano. 2018 Jul 24;12(7):6830-6842. (PMID: 29975503)
Acta Biomater. 2019 Sep 1;95:236-244. (PMID: 30471476)
PLoS One. 2018 Sep 27;13(9):e0204276. (PMID: 30260987)
J Pathol Transl Med. 2018 Jan;52(1):1-8. (PMID: 29370511)
Biochim Biophys Acta. 2013 Oct;1831(10):1509-17. (PMID: 23562840)
Commun Biol. 2019 Sep 3;2:325. (PMID: 31508500)
J Cell Biol. 2013 Feb 18;200(4):373-83. (PMID: 23420871)
Ann Oncol. 2021 Apr;32(4):466-477. (PMID: 33548389)
Am J Cancer Res. 2015 Sep 15;5(10):2929-43. (PMID: 26693050)
Sci Rep. 2019 Sep 10;9(1):13012. (PMID: 31506601)
Nat Cell Biol. 2019 Feb;21(2):190-202. (PMID: 30598531)
Matrix Biol. 2011 Sep;30(7-8):363-8. (PMID: 21723391)
Sci Rep. 2017 Jun 2;7(1):2704. (PMID: 28577337)
Anticancer Res. 2015 Dec;35(12):6379-90. (PMID: 26637847)
PLoS One. 2011;6(9):e24234. (PMID: 21915303)
Eur J Pharm Biopharm. 2022 Jan;170:59-69. (PMID: 34864197)
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77. (PMID: 26858453)
Biomed Res Int. 2015;2015:634865. (PMID: 26601108)
Anticancer Res. 2015 May;35(5):2521-30. (PMID: 25964525)
ACS Nano. 2020 Apr 28;14(4):4444-4455. (PMID: 32282185)
Front Cardiovasc Med. 2018 Dec 21;5:187. (PMID: 30622949)
J Cell Physiol. 2016 Oct;231(10):2128-41. (PMID: 26844415)
J Immunol Methods. 1996 Feb 5;189(2):217-31. (PMID: 8613673)
Mol Ther. 2015 May;23(5):812-823. (PMID: 25868399)
J Extracell Vesicles. 2018 Nov 23;7(1):1535750. (PMID: 30637094)
BMC Cancer. 2020 Sep 29;20(1):929. (PMID: 32993545)
Cell Biol Toxicol. 2020 Apr;36(2):165-178. (PMID: 31820164)
Methods Mol Biol. 2022;2436:183-192. (PMID: 34490596)
J Vis Exp. 2018 Dec 5;(142):. (PMID: 30582600)
Stem Cell Res Ther. 2021 Feb 12;12(1):127. (PMID: 33579358)
J Appl Toxicol. 2017 Mar;37(3):310-318. (PMID: 27435060)
Tissue Eng Part C Methods. 2018 Nov;24(11):637-644. (PMID: 30306827)
J Extracell Vesicles. 2012 Apr 16;1:. (PMID: 24009883)
Front Cell Dev Biol. 2022 Feb 14;10:819726. (PMID: 35237601)
PLoS One. 2014 Oct 17;9(10):e110314. (PMID: 25330373)
J Extracell Vesicles. 2021 Sep;10(11):e12140. (PMID: 34520123)
Cancer Lett. 2019 Sep 28;460:54-64. (PMID: 31233837)
Proteomics. 2019 Apr;19(8):e1700453. (PMID: 30865381)
Theranostics. 2017 Jan 26;7(3):789-804. (PMID: 28255367)
Ci Ji Yi Xue Za Zhi. 2019 Dec 05;32(2):113-120. (PMID: 32269942)
Sci Rep. 2019 May 17;9(1):7538. (PMID: 31101910)
Adv Healthc Mater. 2022 Mar;11(5):e2002067. (PMID: 33890421)
Breast Cancer (Auckl). 2018 Apr 25;12:1178223418767666. (PMID: 29881285)
Methods Mol Biol. 2018;1740:35-41. (PMID: 29388134)
Stem Cell Res Ther. 2019 Sep 23;10(1):288. (PMID: 31547882)
Microorganisms. 2021 May 26;9(6):. (PMID: 34073384)
PLoS One. 2012;7(11):e49221. (PMID: 23155468)
F1000Res. 2020 Nov 23;9:1362. (PMID: 33447385)
J Extracell Vesicles. 2021 Jan;10(3):e12061. (PMID: 33532042)
Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2050-5. (PMID: 17267609)
فهرسة مساهمة: Keywords: CELLine bioreactor; biomanufacturing; breast cancer; exosomes; extracellular vesicles; microvesicles; proteomics
تواريخ الأحداث: Date Created: 20240628 Latest Revision: 20240629
رمز التحديث: 20240629
مُعرف محوري في PubMed: PMC11080891
DOI: 10.1002/jex2.60
PMID: 38938775
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا